Glucagon is a 29-amino acid peptide hormone produced by the alpha cells of the pancreatic islets of Langerhans. It serves as the primary counter-regulatory hormone to insulin, acting to raise blood glucose levels during fasting and hypoglycemia by stimulating hepatic glycogenolysis (glycogen breakdown) and gluconeogenesis (de novo glucose synthesis).

Overview

Glucagon is synthesized as part of the larger proglucagon precursor, which is differentially processed in pancreatic alpha cells and intestinal L-cells. In alpha cells, prohormone convertase PC2 cleaves proglucagon to release glucagon (proglucagon 33-61), while in intestinal L-cells, PC1/3 processing yields GLP-1 and GLP-2 instead. This tissue-specific processing of a single gene product generates hormones with distinct and sometimes opposing metabolic effects — glucagon raises blood glucose while GLP-1 enhances insulin secretion and lowers blood glucose.

Under normal physiology, glucagon is released in response to low blood glucose (hypoglycemia), amino acid ingestion (particularly alanine and arginine), sympathetic nervous system activation (epinephrine, norepinephrine), and exercise. Glucagon secretion is suppressed by hyperglycemia, insulin, somatostatin, and GLP-1. The molar ratio of insulin to glucagon in the portal circulation is a critical determinant of hepatic glucose output — an elevated glucagon-to-insulin ratio promotes net glucose production, while a low ratio promotes glycogen synthesis and lipogenesis.

In type 2 diabetes, glucagon secretion is paradoxically elevated in the fasted state and fails to suppress appropriately after meals, contributing significantly to fasting and postprandial hyperglycemia. This "bihormonal" model of diabetes — involving both insulin deficiency/resistance and glucagon excess — has informed the development of therapies targeting glucagon action, including GLP-1 receptor agonists (which suppress glucagon) and dual GLP-1/glucagon receptor agonists.

Therapeutically, glucagon has been available as an injectable formulation for decades for the emergency treatment of severe hypoglycemia. The development of a stable, room-temperature nasal glucagon formulation (Baqsimi) and a ready-to-use liquid injectable (Gvoke) has significantly improved the usability of glucagon rescue in emergency situations.

Mechanism of Action

Glucagon signals primarily through the glucagon receptor (GCGR) on hepatocytes, activating multiple metabolic pathways:

Hepatic Glycogenolysis: Glucagon binding to GCGR activates Gs-coupled adenylyl cyclase, increasing intracellular cAMP. cAMP activates protein kinase A (PKA), which phosphorylates and activates glycogen phosphorylase kinase, which in turn activates glycogen phosphorylase. Simultaneously, PKA phosphorylates and inactivates glycogen synthase. The net result is rapid breakdown of hepatic glycogen to glucose-1-phosphate, which is converted to glucose-6-phosphate and then free glucose by glucose-6-phosphatase for release into the circulation.

Hepatic Gluconeogenesis: Glucagon stimulates gluconeogenesis through multiple mechanisms. PKA phosphorylates CREB (cAMP response element-binding protein), which upregulates transcription of key gluconeogenic enzymes including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. Glucagon also activates the transcriptional coactivator PGC-1alpha and inhibits the glycolytic enzyme pyruvate kinase, shifting hepatic metabolism toward glucose production from substrates including lactate, amino acids, and glycerol.

Hepatic Lipid Metabolism: Glucagon inhibits de novo lipogenesis and stimulates fatty acid oxidation in hepatocytes by reducing malonyl-CoA levels (through inhibition of acetyl-CoA carboxylase) and activating carnitine palmitoyltransferase 1 (CPT1). This promotes fatty acid entry into mitochondria for beta-oxidation. These lipid-metabolic effects underpin interest in glucagon receptor agonism for treatment of metabolic-associated steatotic liver disease (MASLD/NAFLD).

Cardiac Effects: The heart expresses glucagon receptors, and glucagon produces positive inotropic (increased contractile force) and chronotropic (increased heart rate) effects through cAMP-mediated mechanisms in cardiomyocytes. These effects are independent of beta-adrenergic signaling, which is why glucagon is effective in beta-blocker overdose.

GI Smooth Muscle Relaxation: Glucagon relaxes gastrointestinal smooth muscle, reducing peristalsis and gastric motility. This effect is mediated through cAMP-dependent inhibition of smooth muscle contraction and is exploited clinically during GI radiological and endoscopic procedures.

Reconstitution Calculator

Research

Safety Profile

Glucagon is generally well-tolerated when used at therapeutic doses. The most common adverse effects are nausea and vomiting, which occur in approximately 25-35% of patients receiving rescue doses for hypoglycemia (this is partly attributable to the hypoglycemic event itself). Hyperglycemia following glucagon administration is expected and transient, typically resolving within 60-90 minutes as insulin secretion normalizes blood glucose. Nasal glucagon (Baqsimi) may cause nasal congestion, nasal discomfort, and watery eyes in addition to the systemic effects. At high doses used for cardiac indications (beta-blocker overdose), glucagon commonly causes nausea and vomiting, which can be severe enough to necessitate antiemetic therapy and airway protection. Glucagon is contraindicated in pheochromocytoma (risk of catecholamine surge), insulinoma (paradoxical insulin release worsening hypoglycemia), and in patients with known hypersensitivity. Glucagon should be used cautiously in patients with glycogen depletion (prolonged fasting, adrenal insufficiency, chronic hypoglycemia) as it may be ineffective due to depleted hepatic glycogen stores.

Clinical Research Protocols

• Severe hypoglycemia rescue (adults): 1 mg IM, SC, or IV. Nasal: 3 mg (Baqsimi) in one nostril. Pediatric: 0.5 mg for children <25 kg, 1 mg for >25 kg. May repeat after 15 minutes if no response.
• Gvoke (ready-to-use): 0.5 mg/0.1 mL or 1 mg/0.2 mL autoinjector or prefilled syringe. No reconstitution needed. Room temperature stable.
• GI imaging/endoscopy: 0.25-1 mg IV (onset 1 min, duration 10-20 min) or 1-2 mg IM (onset 8-10 min, duration 20-30 min).
• Beta-blocker/CCB overdose: 3-10 mg IV bolus over 3-5 minutes, followed by infusion at 3-5 mg/hour (titrate to hemodynamic response). Glucagon dose may need frequent uptitration.
• Dual-hormone artificial pancreas: Subcutaneous mini-glucagon boluses (150-300 mcg) delivered by pump algorithm to prevent hypoglycemia. Dasiglucagon (Zegalogue, stable liquid glucagon) developed specifically for pump use.
• Key trials: Baqsimi phase 3 (PMID: 31233362), Gvoke bioequivalence, dual-hormone AP trials (various).
• Duration: Single rescue dose. GI procedures: single dose. Overdose: continuous infusion for hours to days. AP: ongoing micro-doses.

Subpopulation Research

• Type 1 diabetes: Alpha cell dysfunction leads to impaired glucagon counterregulation during hypoglycemia, increasing the risk of severe hypoglycemic events. Exogenous glucagon rescue is critical in this population.
• Type 2 diabetes: Alpha cell hyperfunction with elevated fasting glucagon and impaired meal-mediated suppression contributes to hyperglycemia. Therapies targeting glucagon excess (GLP-1 RAs, DPP-4 inhibitors) address this.
• Pediatric severe hypoglycemia: Mini-dose glucagon (10-20 mcg/kg SC, max 150 mcg) has been studied for mild-to-moderate hypoglycemia prevention in children with type 1 diabetes, providing an alternative to oral glucose.
• Congenital hyperinsulinism: Continuous glucagon infusion as a bridge therapy while awaiting genetic diagnosis and surgical planning.
• Post-bariatric surgery hypoglycemia: Glucagon rescue for post-bariatric late dumping hypoglycemia; also being investigated as part of dual-hormone pump systems in this population.
• Liver disease/glycogen depletion: Glucagon may be ineffective in patients with cirrhosis, prolonged starvation, or adrenal insufficiency due to depleted hepatic glycogen stores.

Pharmacokinetic Profile

Ongoing & Future Research

• Dual-hormone artificial pancreas: Multiple groups advancing closed-loop systems pairing insulin pumps with glucagon pumps. Key challenges include glucagon stability in pump reservoirs and optimal dosing algorithms. Dasiglucagon (Zealand Pharma) designed specifically for pump compatibility.
• MASH/NAFLD treatment (dual agonists): Survodutide (BI 456906) in phase 3 for MASH and obesity. Cotadutide in phase 2b for MASH with liver fibrosis. These leverage glucagon's hepatic lipid-mobilizing effects.
• Retatrutide (triple agonist): Phase 3 program for obesity and type 2 diabetes. Combines GIP/GLP-1/glucagon receptor agonism for potentially best-in-class weight loss.
• Glucagon receptor antagonists: Small molecules blocking the glucagon receptor (e.g., volagidemab) studied for type 1 diabetes to reduce insulin requirements and improve glycemic control. Concerns about alpha cell hyperplasia with chronic blockade.
• Oral glucagon: Development of oral rescue formulations for hypoglycemia that could be administered to semi-conscious patients (buccal, sublingual).
• Glucagon in critical care: Investigation of glucagon's role in managing hemodynamic instability in ICU settings beyond toxicology, including post-cardiac surgery low output states.